Wegovy podría ser una nueva opción valiosa para los pacientes con insuficiencia cardiaca
VIERNES, 25 de agosto de 2023 (HealthDay News) — Wegovy (semaglutida), un medicamento para perder peso, y un medicamento relacionado dirigido a la diabetes, Ozempic, ya han alterado el tratamiento tanto de la obesidad como de la diabetes, y las venta…
Learn MoreWegovy May Be Valuable New Option for Heart Failure Patients
FRIDAY, Aug. 25, 2023 (HealthDay News) — Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.Now, injected Wegovy could…
Learn More¿Cuál es su ‘zona de quema de grasa’ en el ejercicio?
LUNES, 14 de agosto de 2023 (HealthDay News) — Quizá sea necesario adoptar un método más personalizado para el ejercicio, afirma un nuevo estudio, que encontró que la quema de grasa variaba mucho entre los individuos. Y lo que es incluso peor, esta t…
Learn MoreEn medio de la escasez, el fabricante de Wegovy anuncia que las restricciones continuarán hasta 2024
VIERNES, 11 de agosto de 2023 (HealthDay News) — Mientras la demanda del popularísimo medicamento para perder peso Wegovy continúa en aumento, el fabricante del fármaco, Novo Nordis, anunció el jueves que continuará con las restricciones de las dosis…
Learn MoreWhat’s Your Exercise ‘Fat-Burning Zone’?
MONDAY, Aug. 14, 2023 (HealthDay News) — A more personalized approach to exercise may be necessary, claims a new study that found fat burning varied widely between individuals. Even worse, this rate often does not align with the “fat-burning zone” on…
Learn MoreAmid Shortages, Maker Says Restrictions on Wegovy Will Continue Into 2024
FRIDAY, Aug. 11, 2023 (HealthDay News) — As demand for the wildly popular weight-loss drug Wegovy continues to climb, drug maker Novo Nordisk said Thursday that it will continue restrictions on starter doses of the medication into 2024. The new plan …
Learn MoreAmid Shortages, Maker Says Restrictions on Wegovy Will Continue Into 2024
FRIDAY, Aug. 11, 2023 (HealthDay News) – As demand for the wildly popular weight-loss drug Wegovy continues to climb, drug maker Novo Nordisk said Thursday that it will continue restrictions on starter doses of the medication into 2024.The new plan ex…
Learn MoreOdds of Clinically Meaningful Weight Loss Low in Adults With Overweight, Obesity
WEDNESDAY, Aug. 9, 2023 (HealthDay News) — Among adults with overweight or obesity, the annual probability of weight loss of 5 percent or more was achieved by only one in 10, according to a study published online Aug. 7 in JAMA Network Open.Lyudmyla …
Learn MoreEn un nuevo ensayo, Wegovy redujo los riesgos cardiacos de los usuarios
MARTES, 8 de agosto de 2023 (HealthDay News) — Un ensayo clínico de gran tamaño que sopesó los méritos de Wegovy, un fármaco para la obesidad, descubrió un significativo efecto secundario positivo. Tomar el fármaco redujo el riesgo de problemas cardi…
Learn MoreWegovy Lowered Users’ Heart Risks in New Trial
TUESDAY, Aug. 8, 2023 (HealthDay News) — A large clinical trial weighing the medical merits of the obesity drug Wegovy (semaglutide) has unearthed a significant positive side effect. Taking the medication cut the risk for serious heart problems by 20…
Learn More